Cargando…
Recurrent hepatogastric fistula during lenvatinib therapy for advanced hepatocellular carcinoma managed by over-the-scope clip closure: a case report
Objective: Lenvatinib is an oral multitarget tyrosine kinase inhibitor (mTKI) and is recommended for patients with advanced hepatocellular carcinoma (HCC) with Child-Pugh A liver function, who are not amenable to surgical resection, locoregional treatment, or transcatheter arterial chemoembolization...
Autores principales: | Miwa, Takao, Kochi, Takahiro, Watanabe, Keitaro, Hanai, Tatsunori, Imai, Kenji, Suetsugu, Atsushi, Takai, Koji, Shiraki, Makoto, Katsumura, Naoki, Shimizu, Masahito |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Japanese Association of Rural Medicine
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8016677/ https://www.ncbi.nlm.nih.gov/pubmed/33833836 http://dx.doi.org/10.2185/jrm.2020-044 |
Ejemplares similares
-
Mac-2-binding protein glycosylation isomer is useful to predict muscle cramps in patients with chronic liver disease
por: Miwa, Takao, et al.
Publicado: (2022) -
Lenvatinib or Sorafenib Treatment Causing a Decrease in Skeletal Muscle Mass, an Independent Prognostic Factor in Hepatocellular Carcinoma: A Survival Analysis Using Time-Varying Covariates
por: Imai, Kenji, et al.
Publicado: (2023) -
Rapid Depletions of Subcutaneous Fat Mass and Skeletal Muscle Mass Predict Worse Survival in Patients with Hepatocellular Carcinoma Treated with Sorafenib
por: Imai, Kenji, et al.
Publicado: (2019) -
Rapid Depletion of Subcutaneous Adipose Tissue during Sorafenib Treatment Predicts Poor Survival in Patients with Hepatocellular Carcinoma
por: Imai, Kenji, et al.
Publicado: (2020) -
Increased Visceral Adipose Tissue and Hyperinsulinemia Raise the Risk for Recurrence of Non-B Non-C Hepatocellular Carcinoma after Curative Treatment
por: Imai, Kenji, et al.
Publicado: (2021)